Join the club for FREE to access the whole archive and other member benefits.
Goal is to develop drugs that target epigenetic mechanisms associated with neurodegeneration
Key points from article :
Juvenescence Limited aims to develop therapies to treat diseases of ageing and increase human longevity.
Dr. Ellen Donnelly joins the Juvenescence team as the CEO of the Epigenetics Division of Juvenescence.
She is also the CEO of Juvenescence's pipeline company, Souvien Bio Ltd.
She has a big pharma background in Neuroscience at Pfizer as well as knowledge of capital markets.
Her role will help to increase Juvenescence’s portfolio in neurodegeneration and immunology.
Click on resource name for more details.
Biotech company of the life sciences company Juvenescence is focused on developing new therapies to modulate essential epigenetic mechanisms associated with neurodegeneration
